Company intelligence / Profile preview
Replay
San Diego, California, United Statesreplay.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Replay launched with $55 million seed funding to develop interconnected next-generation technology platforms aimed at solving critical problems in genomic medicine. The company’s focus includes reprogramming biology by writing and delivering large DNA sequences using advanced viral vectors such as HSV. It separates core technology development from product companies, enabling broad application across disease areas. Clinical results are not yet available as the company remains preclinical/platform-focused.
- Modalities
- Gene therapy (using HSV vectors)Genome writing/big DNA deliverySynthetic biology platforms
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Replay.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Replay.